Citius Pharmaceuticals (CTXR) Cash & Equivalents (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 17 years of Cash & Equivalents data on file, last reported at $4.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 17280.44% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 17280.44% YoY) and the FY2025 annual result came in at $4.3 million, up 30.76% from the prior year.
• Cash & Equivalents retreated to $4.6 million in Q1 2026, from $7.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $55.8 million in Q1 2022 to a low of $26410.0 in Q1 2025.
• A 5-year average of $20.5 million and a median of $17.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 99.79% — and 2026, when it surged 17280.44%.
• Tracing CTXR's Cash & Equivalents over 5 years: stood at $36.9 million in 2022, then sank by 44.84% to $20.3 million in 2023, then plunged by 94.59% to $1.1 million in 2024, then surged by 601.89% to $7.7 million in 2025, then slumped by 40.55% to $4.6 million in 2026.
• The last three Cash & Equivalents figures came in at $4.6 million (Q1 2026), $7.7 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.